Key result
Tedisamil is a bradycardic agent with a plasma half-life of about 10 hours that reduces myocardial oxygen demand, but its clinical utility is limited by its tendency to increase blood pressure.
Population
Patients with ischaemic heart disease, coronary artery disease, and heart failure, as well as animal models
Design
Review
Authors
Loading...
May limit tedisamil to research settings due to pressor effects; leaves open whether analogs can preserve bradycardic benefits without raising BP.
While tedisamil effectively reduces heart rate and acts as a class III anti-arrhythmic, its clinical utility is limited by its tendency to increase blood pressure.
Sheila A Doggrell (2001) conducted a review in Ischaemic heart disease. Tedisamil was evaluated. Tedisamil is a bradycardic agent with a plasma half-life of about 10 hours that reduces myocardial oxygen demand, but its clinical utility is limited by its tendency to increase blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: